Results 11 to 20 of about 5,411,820 (260)

Region Specific miRNA-mRNA Networks in Gray and White Matter Lesions of Progressive Multiple Sclerosis. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective Multiple sclerosis (MS) is a neurodegenerative demyelinating disease of the central nervous system. This study aimed to identify micro‐RNA (miRNA)–mRNA regulatory networks underlying region‐specific molecular mechanisms in white matter and gray matter lesions in progressive MS.
Sapra A, Rai NK, Niepokny TD, Courtney H, Tripathi A, Dutta R.   +5 more
europepmc   +2 more sources

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. Methods This is a single‐center retrospective cohort study of RRMS patients with cross‐sectional and longitudinal analyses of clinical and MRI data. Future SPMS converters were matched by age, sex,
El Ayoubi NK, Al Ghazal S, Hannoun S, Siddik MA, Najjar NM, Dagher J, Abboud J, Semaan MG, Khoury SJ.   +8 more
europepmc   +2 more sources

Disease Course After Anti-CD20 Discontinuation in Secondary Progressive Multiple Sclerosis-A Multicenter Long-Term Longitudinal Study. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Otto F, Kliushnikova D, Radlberger RF, Yasaroglu S, Moser T, Harrer A, Kratzer K, Hitzl W, Gradl C, Schmidauer M, Roth P, Hegen H, Wipfler P.   +12 more
europepmc   +2 more sources

External validation of a clinical prediction model in multiple sclerosis [PDF]

, 2023
Background: Timely initiation of disease modifying therapy is crucial for managing multiple sclerosis (MS). Objective: We aimed to validate a previously published predictive model of individual treatment response using a non-overlapping cohort from the ...
Inshasi, Jihad, Malpas, Charles B, Yamout, Bassem I., Altıntaş, Ayşe, Yamout, Bassem, Türkoǧlu, Recai, Sharmin, Sifat, Shalaby, Nevin Mohieldin, Karabudak, Rana, Al-Harbi, Talal, Shalaby, Nevin, Shaygannejad, Vahid, Khoury, Samia J., Khoury, Samia J, Boz, Cavit, Soysal, Aysun, Alroughani, Raed, Inshasi, Jihad Said, Terzi, Murat, Moradi, Nahid, Malpas, Charles B., Alroughani, Raed A., Al-Harbi, Talal M., Kalincik, Tomas, Altintaş, Ayşe   +24 more
core   +1 more source

Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS [PDF]

, 2012
Despite significant progress in the development of therapies for relapsing MS, progressive MS remains comparatively disappointing. Our objective, in this paper, is to review the current challenges in developing therapies for progressive MS and identify ...
Salvetti, M, D. Brown, T. Coetzee, K. Sharrock, Lee, K, Brown, D, Feinstein, A, Thompson, A, K. Zuidwijk, D. Chandraratna, Kapoor, R, Fox, RJ, Zuidwijk, K, K. Lee, A. Thompson, G. Comi, Toosy, A, Baneke, P, Browne, P, Sharrock, K, O. Ciccarelli, P. Browne, A. Feinstein, Comi, G, R. J. Fox, Chandraratna, D, P. Zaratin, Baker, D, R. Kapoor, Ciccarelli, O, Zaratin, P, P. Baneke, Coetzee, T, D. Baker, SALVETTI, Marco, A. Toosy   +35 more
core   +1 more source

Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis [PDF]

, 2022
Background: Neurogenic lower urinary tract dysfunction (LUTD) results in lower urinary tract symptoms (LUTS) that impact quality of life in people with multiple sclerosis (PwMS).
Saraceno, Taylor J., Gopal, Arpita, Hauser, Stephen L., Polgar-Turcsanyi, Mariann, Chitnis, Tanuja, Cree, Bruce Anthony C.C., Kaplan, Tamara Bockow, Khoury, Samia J., Santaniello, Adam V., El-Ayoubi, Nabil K., Weiner, Howard L., Block, Valerie J., Gomez, Refujia, Consortium, Summit, Suskind, Anne M., Bové, Riley Marie, Zhao, Chao   +16 more
core   +1 more source

Cerebrospinal fluid ATP metabolites in multiple sclerosis [PDF]

, 2010
Increased axonal energy demand and mitochondrial failure have been suggested as possible causes for axonal degeneration and disability in multiple sclerosis.Our objective was to test whether ATP depletion precedes clinical, imaging and biomarker evidence
Uitdehaag, BMJ, Di Pietro, V., Barkhof, F., Killestein, J, Belli, A.; id_orcid, Killestein, J., Uitdehaag, B.M.J., Eikelenboom, M.J., University of Catania, Tavazzi, B, Petzold, A.F.S., Petzold, A., Petzold, A, Belli, A., Eikelenboom, MJ, Lazzarino, G., Lazzarino, G, Di Pietro, V, Polman, CH, Amorini, A.M., Barkhof, F, Tavazzi, B., Polman, C.H., Belli, A, Di Pietro, V.; id_orcid, Amorini, AM, Pietro, V. Di   +26 more
core   +1 more source

Treatment of multiple sclerosis in special populations: The case of refugees [PDF]

, 2020
Multiple sclerosis was long considered a relatively rare entity in the Middle East, but research over the past 10 years and the publication of the Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis guidelines for multiple
Yamout, Bassem I., Zeineddine, Maya M.
core   +1 more source

Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a. [PDF]

, 2004
S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled ...
Lim, Ee Tuan, Leary, Siobhan M, Geoff Keir, Petzold, Axel, Thompson, Alan J, Gavin Giovannoni, Siobhan M Leary, Altmann, Daniel R, Keir, Geoff, Ee Tuan Lim, David H Miller, Ed J Thompson, Giovannoni, Gavin, Miller, David H, Alan J Thompson, Daniel R Altmann, Thompson, Ed J, Axel Petzold   +17 more
core   +2 more sources

T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis [PDF]

, 2010
Objectives: Prediction of long term clinical outcome in patients with primary progressive multiple sclerosis (PPMS) using imaging has important clinical implications, but remains challenging.
Polman, C., Barkhof, F., Montalban, X, CHARD D, Thompson, A, Polman, C, F. Barkhof, Chard, D, Samson, R., D. Miller, Bodini, B., A. Thompson, Samson, R, MONTALBAN X, R. Samson, Rovira, A, POLMAN C, KHALEELI Z, O. Ciccarelli, Filippi, M., N. De Stefano, Barkhof, F, BATTAGLINI, MARCO, B. Bodini, A. Rovira, Battaglini, M, Polman, C.H., Chard, D., CICCARELLI O., Miller, D., Rovaris, M, Battaglini, M., Thompson, A., De Stefano, N., X. Montalban, MILLER D, ROVARIS M, FILIPPI M, D. Chard, Khaleeli, Z, SAMSON R, ROVIRA A, THOMPSON A, Rovaris, M., De Stefano, N, Rovira, A., Z. Khaleeli, Bodini, B, BODINI B, M. Filippi, Miller, D, BARKHOF F, DE STEFANO, NICOLA, M. Rovaris, Montalban, X., Ciccarelli, O., Ciccarelli, O, Khaleeli, Z., M. Battaglini, C. Polman, Filippi, M, Rovira, Alex, Stefano, N. De, Rovaris, Marco, Thompson, Alan, De Stefano N, Battaglini M, FILIPPI , MASSIMO, Barkhof, Frederik, Polman, Chris, Montalban, Xavier, Ciccarelli, Olga, Miller, David, Filippi, Massimo, Khaleeli, Zhaleh, Chard, Declan, Filippi, M., Bodini, Benedetta, Samson, Rebecca   +78 more
core   +1 more source